Sharekhan's research report on Biocon
Biocon’s Q2FY22 results were healthy but the operating performance marginally missed estimates. Due to higher other income, the adjusted PAT was ahead of estimates Reducing impact of pandemic and expected improvement in supply chain systems bodes well for all three segments - Generics, Biosimilars and research services from a growth perspective. Expected strong traction in biologics, driven by focus on oncology and insulin portfolio, new tie ups facilitating entry in new areas of vaccines & communicable diseases make biologics a key growth driver.
Outlook
We retain Buy on the stock of Biocon with an unchanged price target (PT) of Rs. 470.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
